PDS Biotechnology Corp (PDSB) Form 8-K — Oct 20, 2026
$PDSBForm 8-KItems 5.02, 8.01, 9.01Filed Oct 20, 2026, 8:00 AM ET0001140361-26-040181Original filing
PDS Biotechnology announced on October 20, 2026 that four directors — Kamil Ali-Jackson, Stephen Glover, Gregory Freitag and Otis Brawley — resigned effective October 18, with the company stating none resulted from disagreement over operations, policies or practices. The board appointed three pharma industry veterans: John Dawson CBE (former Oxford Biomedica CEO), Deborah Ramsdell (rare-disease regulatory expert), and Bruce Wendel (former Abraxis CEO, current ImmunityBio director), keeping the authorized board at seven with one vacancy remaining.
Key figures
- Directors resigned
- 4
- Directors appointed
- 3
- Authorized board size
- 7
- New director option shares each
- 22700
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.